Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Auditor change
Acorda Therapeutics, Inc. (ACOR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Second Quarter 2023 Financial Results • INBRIJA® Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million • New INBRIJA prescription request forms increased 42% in 1H 2023 over 2022 • AMPYRA® Extended Release Tablets, 10 mg Q2 2023 net revenue of $16.9 million, a 7% decrease from Q2 2022; FAMPYRA royalty revenue of $2.9 million • 2023 INBRIJA U.S. net revenue, adjusted operating expenses, and year-end cash guidance revised • Company does not expect to be cash flow neutral in 2023 • Nasdaq compliance regained after 1-for-20 reverse split"
05/11/2023 8-K Quarterly results
Docs: "Acorda Therapeutics Reports First Quarter 2023 Financial Results • INBRIJA® Q1 2023 U.S. net revenue of $5.6 million, a 52% increase from Q1 2022; ex-U.S. net revenue of $0.5 million • AMPYRA® Extended Release Tablets, 10 mg Q1 2023 net revenue of $12.6 million, a 15% decrease from Q1 2022; FAMPYRA royalty revenue of $2.9 million • 2023 financial guidance reaffirmed • Agreement with Chance Pharmaceuticals to commercialize INBRIJA in China • Tom Burns, Chief Financial Officer of XOMA, to be candidate for Board of Directors at 2023 Annual Meeting of Stockholders; Jeff Randall to rotate off the Board"
08/04/2022 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Second Quarter 2022 Financial Results"
05/16/2022 8-K/A Quarterly results
05/11/2022 8-K Quarterly results
03/18/2022 8-K/A Quarterly results
Docs: "Corrected Press Release Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results"
03/09/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team",
"Acorda Therapeutics Announces Agreement to Commercialize INBRIJA ® in Germany"
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/03/2020 8-K Quarterly results
Docs: "Acorda Reports Third Quarter 2020 Financial Results"
08/04/2020 8-K Quarterly results
05/05/2020 8-K Quarterly results
02/13/2020 8-K Quarterly results
11/04/2019 8-K Quarterly results
Docs: "Acorda Provides Update for Third Quarter Ended September 30, 2019"
08/01/2019 8-K Quarterly results
Docs: "Acorda Provides Update for Second Quarter Ended June 30, 2019"
05/02/2019 8-K Quarterly results
Docs: "Acorda Provides Update for First Quarter Ended March 31, 2019"
10/31/2018 8-K Quarterly results
Docs: "INBRIJA™ in Parkinson’s disease - In September, the FDA extended the PDUFA goal date for its review of the New Drug Application of INBRIJA from October 5, 2018 to January 5, 2019 based on submissions the Company made in response to requests from FDA for additional information on chemistry, manufacturing and controls . FDA determined that these submissions constituted a major amendment and will take additional time to review. - The Company reported that the inspection of its Chelsea, Massachusetts manufacturing facility and the Inbrija inhaler device manufacturer's facility were successfully completed and closed without need for any further action by the FDA. - INBRIJA is an investigational treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/lev..."
08/02/2018 8-K Quarterly results
Docs: "INBRIJA - The Company’s Marketing Authorization Application for INBRIJA was validated by the European Medicines Agency and the application currently is under review. After the adoption of an opinion on the application by the Agency’s Committee for Medicinal Products for Human Use , a final decision regarding the MAA will be issued by the European Commission. - In June, the Company presented four INBRIJA abstracts at the 2nd Pan American Parkinson’s Disease and Movement Disorders Congress in Miami. These data were previously presented at the American Academy of Neurology Annual Meeting in April 2018. • AMPYRA Patent Appeal - In June, the oral argument in the AMPYRA patent litigation took place at the U.S. Court of Appeals for the Federal Circuit. The Company is awaiting the Court’s d..."
05/02/2018 8-K Quarterly results
Docs: "INBRIJA - In February, the FDA notified the Company that it had accepted for filing the New Drug Application for INBRIJA. Under the Prescription Drug User Fee Act , the FDA has set a target date of October 5, 2018 for issuing its decision on the NDA. - In March, the Company submitted a Marketing Authorization Application to the European Medicines Agency for INBRIJA. Acorda is seeking approval to market INBRIJA in the European Union. - In April, the Company presented new INBRIJA data from four accepted abstracts during two oral platform presentations at the American Academy of Neurology Annual Meeting in Los Angeles. A safety assessment in early morning OFF symptoms in patients with Parkinson’s disease was presented by Dr. Stuart H. Isaacson and Dr. Robert H. Hauser; long-term pulmonary saf..."
10/31/2017 8-K Quarterly results
07/27/2017 8-K Quarterly results
Docs: "INBRIJA in Parkinson’s disease - In June, the Company submitted a New Drug Application to the U.S. Food and Drug Administration for INBRIJA. The NDA was submitted as a 505 application. - In June, data from the Phase 3 SPAN-PD clinical trial of INBRIJA was presented at the International Congress of Parkinson’s Disease and Movement Disorders . • Tozadenant in Parkinson’s disease - In June, data from clinical and preclinical studies of tozadenant were presented at the 2017 International Congress of Parkinson’s Disease and Movement Disorders . One of the three posters presented, “Efficacy of tozadenant in animal models of non-motor symptoms of Parkinson's disease,” was selected by MDS for the Blue Ribbon Session, which highlights the best scientific posters at the conference. • A..."
04/27/2017 8-K Form 8-K - Current report
10/27/2016 8-K Form 8-K - Current report
07/28/2016 8-K Quarterly results
Docs: "Acorda Provides Financial and Pipeline Update for Second Quarter 2016"
04/28/2016 8-K Quarterly results
Docs: "Acorda Provides Financial and Pipeline Update for First Quarter 2016 · AMPYRA® 1Q 2016 net revenue of $109.6 Million; 19% increase over 1Q 2015 net revenue of $92.4 Million · Company exceeds 90% minimum condition to close Biotie acquisition; final close expected in 2H 2016 · Diversified portfolio with potential for three NDA filings by the end of 2018 ARDSLEY, N.Y. – April 28, 2016 – Acorda Therapeutics, Inc. today provided a financial and pipeline update for the first quarter ended March 31, 2016. AMPYRA® 1Q 2016 net revenue was $109.6 Million, a 19% increase over 1Q 2015 net revenue of $92.4 Million. In January 2016, the Company announced an agreement to acquire Biotie, and has received more than 90% of Biotie’s outstanding shares in the tender offer. The Company expects to complete the ..."
10/31/2013 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Third Quarter 2013 Financial Results · AMPYRA® Third Quarter Net Revenue of $77.8 Million · Narrowing 2013 AMPYRA Net Revenue Guidance to $295-$305 Million · Lowering R&D Expense Guidance to $45-$55 Million; Lowering SG&A Expense Guidance to $165-$175 Million"
08/01/2013 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Second Quarter 2013 Financial Results · AMPYRA® Second Quarter Net Revenue of $77.8 Million · Reiterating 2013 AMPYRA Net Revenue Guidance of $285-$315 Million · Completed Acquisition of Neuropathic Pain Management Products Qutenza® 8% Patch and NP-1998"
05/02/2013 8-K Quarterly results
Docs: "Acorda Therapeutics Reports First Quarter 2013 Financial Results · AMPYRA First Quarter Net Revenue of $62.3 Million; Reiterating Full Year 2013 Guidance for AMPYRA Net Revenue of $285-$315 Million · Combined First Quarter Zanaflex Franchise and ex-U.S. FAMPYRA Royalty and License Revenue of $9.5 Million"
10/31/2012 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Third Quarter 2012 Financial Results · AMPYRA® Third Quarter Net Revenue of $69.8 Million · Combined Third Quarter ZANAFLEX Franchise and ex-U.S. FAMPYRA® Royalty Revenue of $5.3 Million"
07/31/2012 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Second Quarter 2012 Financial Results · AMPYRA® Second Quarter Net Revenue of $66.3 Million · Combined Second Quarter ZANAFLEX Franchise and ex-U.S. FAMPYRA® Royalty Revenue of $7.1 Million"
05/03/2012 8-K Quarterly results
Docs: "Acorda Therapeutics Reports First Quarter 2012 Financial Results · AMPYRA® First Quarter Net Revenue of $57.4 Million · AMPYRA 2012 Net Revenue Guidance of $255-$275 Million Reaffirmed · Combined First Quarter ZANAFLEX Franchise and ex-U.S. FAMPYRA® Royalty Revenue of $11.6 Million"
02/16/2012 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Fourth Quarter and Full Year 2011 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy